Urethral reconstruction with autologous urine-derived stem cells seeded in three-dimensional porous small intestinal submucosa in a rabbit model
© The Author(s). 2017
Received: 29 October 2016
Accepted: 9 February 2017
Published: 9 March 2017
Urethral reconstruction is one of the great surgical challenges for urologists. A cell-based tissue-engineered urethra may be an alternative for patients who have complicated long strictures and need urethral reconstruction. Here, we demonstrated the feasibility of using autologous urine-derived stem cells (USCs) seeded on small intestinal submucosa (SIS) to repair a urethral defect in a rabbit model.
Autologous USCs were obtained and characterized, and their capacity to differentiate into urothelial cells (UCs) and smooth muscle cells (SMCs) was tested. Then, USCs were labeled with PKH67, seeded on SIS, and transplanted to repair a urethral defect. The urethral defect model was surgically established in New Zealand white male rabbits. A ventral urethral gap was created, and the urethral mucosa was completely removed, with a mean rabbit penile urethra length of 2 cm. The urethral mucosal defect was repaired with a SIS scaffold (control group: SIS with no USCs; experimental group: autologous USC-seeded SIS; n = 12 for each group). A series of tests, including a retrograde urethrogram, histological analysis, and immunofluorescence, was undertaken 2, 3, 4, and 12 weeks after the operation to evaluate the effect of the autologous USCs on urethral reconstruction.
Autologous USCs could be easily collected and induced to differentiate into UCs and SMCs. In addition, the urethral caliber, speed of urothelial regeneration, content of smooth muscle, and vessel density were significantly improved in the group with autologous USC-seeded SIS. Moreover, inflammatory cell infiltration and fibrosis were found in the control group with only SIS, but not in the experimental autologous USC-seeded SIS group. Furthermore, immunofluorescence staining demonstrated that the transplanted USCs differentiated into UCs and SMCs in vivo.
Autologous USCs can be used as an alternative cell source for cell-based tissue engineering for urethral reconstruction.
KeywordsUrine-derived stem cells Tissue engineering Urethral reconstruction
Reconstruction of the adult and pediatric male penile urethra has been one of the great surgical challenges for urologists, especially in cases of recurrent hypospadias and long urethral defects after trauma. More than 200 different reconstructive methods for urethral stricture disease or congenital absence have been described, with a variety of donor tissues, such as free skin grafts , bladder mucosa , buccal mucosa , and lingual mucosa , proving successful for urethral reconstruction. However, in many cases, an adequate amount of donor tissue is not available . In addition, substantial donor site morbidity, including submucosal scarring, pain, numbness, injury to salivary ducts, and limitation of mandibular movement, has been reported . Furthermore, complications, such as fistulae, hair growth, graft shrinkage, strictures, stone formation, and diverticulum, occur in the long term following the procedure .
The use of tissue-engineered grafts to repair urethral defects is considered to be an approach with therapeutic potential. Natural collagen materials, such as bladder submucosa (BSM) [8, 9], small intestinal submucosa (SIS) , or collagen type I matrix , have already been successfully used in urological tissue engineering for short urethral defects both experimentally  and clinically . Previous studies [8, 14] demonstrated that a SIS decellularization procedure including a 5% peracetic acid (PAA) treatment step leads to higher porosity and larger pore size. These porous microstructures allow cell infiltration into the matrix and have fewer heterogeneous cellular proteins, thereby preventing complications, such as inflammatory reactions, fibrosis, calcification, and graft shrinkage.
Another critical element required for successful urethral tissue engineering is the cell source. A subpopulation of stem cells can be easily isolated from human voided urine [15–17], i.e., urine-derived stem cells (USCs). USCs are multipotent cells that have been widely demonstrated to terminally differentiate into a variety of different cell types, including smooth muscle cells (SMCs) and uroepithelial, endothelial, osteogenic, adipogenic, chondrogenic, and neural lineages . Furthermore, autologous USCs can be harvested using a simple, safe, low-cost, and non-invasive procedure. Thus, USCs may be an excellent alternative cell source for urological tissue engineering applications.
Therefore, we cultured autologous rabbit USCs before surgery and seeded them onto a 5% PAA-treated SIS scaffold to reconstruct the urethra in rabbits. This cell-based tissue-engineered urethra may be useful to patients with complicated long strictures who need urethral reconstruction.
SIS scaffold preparation
Fresh porcine small intestines were obtained and chemically modified according to a protocol published previously by Liu et al. . The mucosa and serosa were mechanically removed and washed in distilled water. For decellularization, SIS samples were treated with 5% PAA for 4 h with agitation on an orbital shaker at 200 rpm at 4 °C. After decellularization, they were treated with 1% Triton X-100 for a further 2 days. Then, the SIS was washed in distilled water for another 72 h. Finally, the SIS scaffold was sterilized using 0.1% PAA prepared in 20% ethanol for 2 h, rinsed six times with sterile phosphate buffer solution for 20 min each time, and stored in sterile phosphate buffer solution containing 100 U/ml penicillin and 0.1 mg/ml streptomycin at 4 °C until needed.
Scanning electron microscopy
Fresh SIS and 5% PAA-treated SIS were fixed in 2.5% glutaraldehyde. The SIS samples were frozen at –80 °C for 24 h, sputter-coated with gold, and mounted for analysis. Electron micrographs of mucosa slides were obtained with an acceleration voltage of 25.0 kV at a magnification of 400× using a Hitachi S-3000 N Scanning Electron Microscope (Hitachi Technologies America, Pleasanton, CA, USA).
For measurement of residual DNA, fresh SIS and 5% PAA-treated SIS samples were dabbed dry with tissue paper and weighed. Samples were minced, and any remaining nucleic acids were extracted using a commercially available kit (DNeasy™, Qiagen, Valencia, CA, USA). The DNA concentration in each sample was calculated using a UV spectrophotometer (ND-2000, NanoDrop Technologies, Wilmington, DE, USA) to measure the absorbance at 260 nm. The DNA yield was normalized to the initial wet weight of the samples.
Isolation of autologous rabbit USCs
Urine and bladder irrigation solution samples (average total volume of approximately 60 ml/sample) were collected from every rabbit that was to undergo surgery. Each sample was centrifuged at 500 g for 5 min to collect the cells, and the supernatant was carefully discarded. The pelleted cells were gently resuspended in medium (a 1:1 mixture of KSFM and embryonic fibroblast medium (EFM)) and plated in 24-well plates for single-cell cultures. The medium was changed every 2 days after the initial 72 h, and cells were passaged at 70–80% confluency .
Urothelial and smooth muscle differentiation of USCs
For urothelial differentiation, USCs were plated at a density of 3000 cells/cm2 in medium composed of equal amounts of KSFM and EFM containing 2% serum and 30 ng/ml epidermal growth factor (R&D Systems, Minneapolis, MN, USA) and cultured for 14 days . The medium was replaced every 3 days, and, on day 14, the cells were analyzed by immunofluorescence (IF) staining and Western blotting for urothelial cell (UC)-specific markers (AE1/AE3).
For SMC differentiation, USCs were plated at a density of 2000 cells/cm2 in myogenic differentiation medium composed of equal amounts of DMEM and EFM containing 10% fetal bovine serum (FBS) as well as 2.5 ng/ml transforming growth factor (TGF)-1 and 5 ng/ml platelet-derived growth factor (PDGF)-BB (R&D systems) . The medium was replaced every 3 days, and, on day 14, the cells were analyzed by IF staining and Western blotting for the SMC-specific marker myosin.
Autologous USC-seeded SIS scaffold preparation and proliferation assay
A suspension of USCs was seeded on the serosal side of the SIS at a density of 2 × 105 cells/cm2. On the third day, the scaffolds were inverted and a similar number of USCs was seeded onto the mucosal side of the SIS. Every 3 days, the scaffolds were inverted. After 14 days of culture, the USC-seeded, 5% PAA-treated SIS scaffolds were ready to use for the experiment.
To analyze the cytotoxicity of the 5% PAA-treated SIS scaffold, CCK-8 assays were performed. USCs cultured in 96-well plates with 5% PAA-treated SIS were compared with USCs cultured in 96-well plates without 5% PAA-treated SIS. Briefly, 1000 USCs were seeded in each well of 96-well plates. After the cells adhered, the medium was removed, and medium containing 5% PAA-treated SIS was added. Cells cultured without scaffolds were used as the control.
Cell labeling and tracking
To detect differentiation of the seeded USCs, USCs were labeled with a PKH67 green fluorescent labeling kit (Sigma Aldrich) following the manufacturer’s protocol. Briefly, USCs were incubated with PKH67 for 5 min and washed four times to remove excess dye. After being labeled, the cells were seeded into SIS scaffolds and transplanted into rabbit urethras. IF was performed 2, 3, and 4 weeks after transplantation for markers of the urothelium (AE1/AE3; Abcam) and smooth muscle (myosin; Abcam).
Rabbit urethra reconstruction utilizing the SIS scaffold
All pre- and post-animal procedures were performed in accordance with guidelines set forth by the Ethics Committee of Chongqing Medical University, and were approved by this committee (license number: SCXK[YU]20110016). Twenty-four New Zealand white male rabbits (2.0–2.5 kg) were randomly divided into two groups, each containing 12 animals. Autologous USCs had been obtained from each of these rabbits and cultured. The experimental group received urethroplasty with an autologous USC-seeded 5% PAA-treated SIS scaffold, and the control group received urethroplasty with a 5% PAA-treated SIS scaffold alone. Animals were anesthetized with pentobarbital (30 mg/kg) administered intravenously and lidocaine (6 mg/kg) administered subcutaneously to decrease any pain during and after the surgery. A ventral urethral gap was created a mean of 2 cm from the external urethral orifice, and the urethral mucosa was exposed and completely removed, with a mean penile urethra length of 2 cm. The urethral mucosal defect was repaired with a SIS scaffold (control group: 5% PAA-treated SIS alone with no USCs; experimental group: autologous USC-seeded 5% PAA-treated SIS; n = 12 for each group). The SIS scaffold ends were anastomosed with the native ends of the urethral tissue using 6-0 absorbable sutures in a water-tight fashion. The wound was closed in layers in a routine fashion. An 8 F silicone catheter was indwelled and fastened with 6-0 absorbable sutures to provide bladder drainage for the 14 days following the operation. Each group was sacrificed at the 2, 3, 4, or 12 week time point. At 12 weeks, the animals in the two groups were assessed with retrograde urethrograms.
Fresh SIS, 5% PAA-treated SIS, USC-seeded 5% PAA-treated SIS, and urethral specimens were fixed in 10% buffered formalin, embedded in paraffin, and processed for histology (hematoxylin and eosin (H&E) staining, 4′,6-diamidino-2-phenylindole (DAPI) staining, Masson’s trichrome staining, immunohistochemistry (IHC), and IF). IHC was performed using monoclonal antibodies against the urothelium (AE1/AE3; Abcam), smooth muscle (myosin; Abcam), and vascular endothelium (CD31; Abcam). Briefly, consecutive 4.0-μm sections were prepared using a cryostat and incubated overnight at 4 °C with the following primary antibodies: anti-AE1/AE3 diluted 1:75, anti-myosin diluted 1:100, and anti-CD31 diluted 1:150. Then, sections were washed with phosphate-buffered saline (PBS) and incubated with the appropriate secondary antibody diluted 1:200 for 60 min at room temperature. Finally, the slides were rinsed twice with PBS and counterstained with hematoxylin or DAPI. IF was performed using monoclonal antibodies against the urothelium (AE1/AE3; Abcam) and smooth muscle (myosin; Abcam). Briefly, frozen sections (6.0 μm) or cells were fixed in 4% paraformaldehyde and blocked with 5% bovine serum albumin. Subsequently, the sections were treated overnight at 4 °C with the following primary antibodies: anti-AE1/AE3 diluted 1:75 or anti-myosin diluted 1:100. They were then incubated with a secondary antibody (IgG labeled with fluorescein) and counterstained with DAPI.
The data are presented as mean and standard error of the mean for each group. Individual comparisons were made between groups using two-tailed Student’s t tests. Differences were considered statistically significant for P values < 0.05.
Histological analysis of the SIS
Scanning electron microscopy
DNA content and proliferation assay
The DNA content analysis (Fig. 2e) showed a decrease in DNA content after 5% PAA treatment. The difference in DNA content between the two groups was significant (P < 0.05). The USCs grew well in medium containing the 5% PAA-treated SIS scaffold, and the OD (optical density) values in the scaffold groups were similar to those in the control group (P > 0.05) (Fig. 2f).
Characteristics and multipotent differentiation of USCs
Seeding of autologous USCs onto SIS scaffolds
Macroscopy and retrograde urethrogram evaluation
Cell labeling and tracking
Histopathological evaluation of retrieved urethras
Many donor tissues have been used for urethral reconstruction, including free skin grafts, bladder mucosa, colonic mucosa, buccal mucosa, and lingual mucosa; however, these are not satisfactory and often lead to complications, such as anastomotic strictures and fistulas [20–22]. Furthermore, the use of these tissues requires the harvesting of tissue from a secondary site, and donor site morbidity has been reported [2, 6, 23–26].
Tissue engineering technology provides an alternative approach to build a functional urethra for patients who require urethral reconstruction. Various biodegradable scaffolds have been introduced for urethral reconstruction, including natural collagen materials [8–11] and synthetic polymers such as poly(glycolic acid)  and poly(lactic-co-glycolic acid) . However, synthetic biomaterials limit the biologically active molecules that allow tissue regeneration across the graft to proceed, and quickly restrict its application . Natural collagen materials are derived from natural tissues. Their cellular components are removed by a combination of mechanical and chemical manipulation, and extracellular matrix components, such as collagen, fibronectin, laminin, glycosaminoglycans, and growth factors, are retained. They have already been successfully used in urological tissue engineering to treat short urethral defects, both experimentally  and clinically , with materials such as BSM [8, 9], SIS , and collagen type I matrix . However, natural collagen materials also have certain disadvantages that limit their clinical application. After conventional decellularization procedures, SIS often does not possess the highly interconnected macroporous or microporous structures that allow cell infiltration into the matrix, and the material retains some heterogeneous cellular proteins. Despite the high density of collagen and residual heterogeneous cellular proteins, the material can block host cells or seeded cells from infiltrating the collagen matrix and lead to complications. In this study, we combined manual agitation (physical) and Triton X-100 treatment with high concentrations of PAA (chemical) for decellularization of SIS. Similar combinations have been successfully used in previous studies [9, 14, 29]. After treatment with 5% PAA, the porosity and pore size, ranging from 10 to 150 nm on the surface, are higher and larger than SIS without PAA treatment, which allows host cells to infiltrate the SIS scaffold  and enhances the transport of nutrients and metabolic waste products [30, 31]. In addition, they are almost completely free of heterogeneous cellular compounds, which could lead to immune reactions, strictures, and fibrosis . Furthermore, the proliferation assay revealed that 5% PAA-treated SIS scaffolds were biocompatible with the USCs. Thus, treatment with 5% PAA contributes to better tissue regeneration.
In addition, the use of acellular matrix is only indicated for short strictures when a healthy and well-vascularized part of the urethral wall exists, with a limit of <1.0 cm for tissue regeneration . Many previous studies [5, 10, 33] have shown that, in urethral reconstruction, cell seeding is necessary to decrease complications when matrices are used. Two types of cells have been introduced for urethral reconstruction. First, adult cells, such as UCs [5, 34, 35], epidermal cells , SMCs , lingual keratinocytes [37, 38], mesothelial cells , and fibroblasts , have often been used. However, culturing of these cells has a low success rate, and they also have a limited expansion capability in culture. Second, stem cells, including mesenchymal stem cells  and adipose-derived stem cells , have been used for tissue engineering. However, these cells have certain disadvantages that limit their clinical application, such as a low differentiation capacity (<5% yield of UCs of endodermal lineage), a short lifespan in vitro (<10 passages for bone marrow stem cells), and the need for invasive collection procedures . In this experiment, we were able to harvest autologous USCs and expand them to sufficient numbers for scaffold seeding using a simple, safe, low-cost, and non-invasive procedure. USCs possess both self-renewal and multilineage differentiation capabilities; they can differentiate into osteocytes, chondrocytes, adipocytes, skeletal myocytes, interstitial cells, and endothelial cells [15, 18]. We demonstrated that USCs were able to differentiate into cells of the smooth muscle lineage (mesodermal origin) and urothelial lineage (endodermal origin) in vitro; therefore, USCs may assume the role of urethral SMCs and UCs. Because the cells were to be grafted into recipients, immunological rejection should be considered. However, autologous cells have no issues relevant to immunological rejection. In addition, as a type of stem cell, USCs also can regulate the immune response by inhibiting inflammatory and immunomodulatory factors.
Previous studies [14, 41] have shown that a 3D porous biological collagen matrix provides favorable conditions for USC expansion and differentiation, and that USC-seeded 3D porous biological collagen matrix can be used to construct a tissue-engineered urethra. It is not clear whether USC-seeded 3D porous biological collagen matrices are an effective therapy in vitro. Data from previous studies [9, 14, 41] were used as a foundation to extend the use of autologous USCs seeded on a 3D porous SIS to construct a tissue-engineered urethra. In this study, we investigated the feasibility and availability of an autologous USC-seeded 3D-porous SIS scaffold to reconstruct the urethra.
In this study, H&E and DAPI staining revealed that autologous USCs were successfully seeded into 3D porous SIS scaffolds on both sides, and the cells attached well and formed a multilayer of cells on the surface of the SIS. Additionally, H&E and AE1/AE3 IHC staining showed integrated epidermal cell layers in the autologous USC-seeded 3D porous SIS scaffold group 2 weeks after the operation. By comparison, stratified epidermal cellular layers were formed at 3 weeks. Despite the infiltration of the host epithelial cells, there was no significant difference in urothelial regeneration between the two groups at 3 months. However, the early integrated epidermal cellular layers attached to the luminal surface of the urethra may provide a permeability barrier that can prevent urine leakage from the underlying tissues, which is one of the major factors implicated in the inflammatory infiltration and fibrous tissue deposition that lead to stricture formation. Importantly, Masson’s trichrome, myosin IHC staining, and functional analysis showed that the animals that received the autologous USC-seeded 3D porous SIS scaffold showed improvement over those that received the 3D porous SIS scaffold alone. SMCs were seen in the autologous USC-seeded 3D porous SIS scaffold group 2 weeks postoperatively. These continued to develop and approximate normal tissues throughout the study with no abnormal findings. By comparison, SMCs began to appear at 3 weeks postoperatively. The smooth muscle-to-collagen ratio and the content of smooth muscle were significantly higher in the autologous USC-seeded 3D porous SIS group than in the 3D porous SIS alone group (P < 0.05) at 3 and 4 weeks and 3 months. Additionally, all of the animals in the 3D porous SIS alone group exhibited strictures, and only one animal in the autologous USC-seeded 3D porous SIS group exhibited minor strictures. The number of vessels was significantly higher in the autologous USC-seeded 3D porous SIS group than in the 3D porous SIS alone group at early time points, which allowed host cells to infiltrate the scaffold and enhanced the transport of nutrients and metabolic waste products, thereby promoting urethral regeneration. We also demonstrated that the native urethra environment in the animal appeared to provide enough stimuli to cause the USCs to differentiate into SMCs and UCs and to assume the role of urethra SMCs and UCs. In addition, USCs secrete a variety of growth factors, such as vascular endothelial growth factor (VEGF), PDGF, PLGF, basic fibroblast growth factor, epidermal growth factor, and TGF-β . VEGF expression enhances muscle regeneration in vivo . This might lead to the recruitment of host cells, a direct effect of angiogenesis, and contribute to the smooth muscle and urothelial layers that repopulate the urethra. These findings indicate that autologous USCs can promote urothelium and smooth muscle regeneration and vessel infiltration and decrease the indwelling time, thus reducing complications, such as infection, scarring, and strictures.
In this study, however, inflammatory cell infiltration and fibrosis were found in the SIS alone group. In addition, all animals in the SIS alone group exhibited strictures, and one animal in the autologous USC-seeded group exhibited minor strictures. Due to the immunomodulatory and immunosuppressive properties of USCs, it is believed that they can secrete immunomodulatory factors after transplantation, including interleukins (ILs; such as IL-2 and IL-12), cytokines (such as interferon and granulocyte colony-stimulating factor), and chemokines (such as macrophage inflammatory protein-1α) , and inhibit peripheral blood mononuclear cell (T and B cell) proliferation . Moreover, in control animals, in which USCs were not seeded on the scaffolds, immunoreaction was one of the major factors implicated in the inflammatory cell infiltration that led to stricture formation. Another contributing factor to the success of urethral reconstruction could be the permeability barrier formed by the USCs. For these reasons, histological analysis and the retrograde urethrogram did not show an immune reaction, an inflammatory response, or stricture formation within the autologous USC-seeded 3D porous SIS scaffold group.
Although this study provides evidence that autologous USC-seeded 3D porous SIS scaffolds can be used to construct a tissue-engineered urethra, it has some limitations. First, we did not analyze the bioactive factors, such as growth factors and cytokines, that are secreted by USCs and which are believed to enhance tissue regeneration. Second, in the present study, the urethral defect models were established in normal animals, which cannot fully simulate the exact clinical situation of urethral strictures, which is characterized by a fibrotic urethral bed. Finally, the number of experimental animals that were evaluated per time point is small. Further investigations are necessary to translate this technology into the clinic.
USCs that can be easily isolated from voided urine can be extensively expanded to high numbers in vitro, and efficiently give rise to UCs and SMCs in vitro and vivo. They can be utilized as a promising cell source for tissue-engineered urethras. In addition, 3D porous SIS as an optimized biomaterial has potential as a cell-based scaffold for tissue-engineered urethra. Furthermore, an autologous USC-seeded 3D porous SIS scaffold could promote urethral regeneration.
Embryonic fibroblast medium
Hematoxylin and eosin
Platelet-derived growth factor
Small intestinal submucosa
Smooth muscle cell
Transforming growth factor
Urine-derived stem cell
Vascular endothelial growth factor
This study was supported by the National Natural Science Foundation of China (grant 81370701).
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.
YL, YZ, DZ, DB, LA, and GW contributed to the conception and design of the study and manuscript preparation. YL, WM, GX, BL, YW, and LS were responsible for the cell culture and differentiation experiments, data collection, and manuscript writing. YL, DH, TL, DZ, JC, and CL were involved in animal experiments, data collection, and manuscript editing. All authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
This manuscript was approved by all authors for publication.
All pre- and post-animal procedures were performed in accordance with guidelines set forth and approved by the Ethics Committee of Chongqing Medical University (license number: SCXK[YU]20110016).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Elmoghazy H, Hussein MM, Mohamed E, et al. A novel technique for repair of mid-penile hypospadias using a preputial skin flap: results of 110 patients. Int Urol Nephrol. 2016;48:1943–9.View ArticlePubMedGoogle Scholar
- Fine R, Reda EF, Zelkovic P, et al. Tunneled buccal mucosa tube grafts for repair of proximal hypospadias. J Urol. 2015;193(5 Suppl):1813–7.View ArticlePubMedGoogle Scholar
- Palmer DA, Marcello PW, Zinman LN, Vanni AJ. Urethral reconstruction with rectal mucosa graft onlay: a novel, minimally invasive technique. J Urol. 2016;196(3):782–6.View ArticlePubMedGoogle Scholar
- Zhang K, Zhou S, Zhang Y, et al. Anterior urethra reconstruction with lateral lingual mucosa harvesting technique. Urology. 2016;90:208–12.View ArticlePubMedGoogle Scholar
- Orabi H, AbouShwareb T, Zhang Y, Yoo JJ, Atala A. Cell-seeded tubularized scaffolds for reconstruction of long urethral defects: a preclinical study. Eur Urol. 2013;63(3):531–8.View ArticlePubMedGoogle Scholar
- Lumen N, Vierstraete-Verlinde S, Oosterlinck W, et al. Buccal versus lingual mucosa graft in anterior urethroplasty: a prospective comparison of surgical outcome and donor site morbidity. J Urol. 2016;195(1):112–7.View ArticlePubMedGoogle Scholar
- Abdelhameed H, Elgamal S, Farha MA, et al. The long-term results of lingual mucosal grafts for repairing long anterior urethral strictures. Arab J Urol. 2015;13(2):128–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang JW, Xie MK, Zhang Y, et al. Reconstruction of penile urethra with the 3-dimensional porous bladder acellular matrix in a rabbit model. Urology. 2014;84(6):1499–505.View ArticlePubMedGoogle Scholar
- Liu Y, Bharadwaj S, Lee SJ, Atala A, Zhang Y. Optimization of a natural collagen scaffold to aid cell-matrix penetration for urologic tissue engineering. Biomaterials. 2009;30(23–24):3865–73.View ArticlePubMedGoogle Scholar
- Guo H, Sa Y, Huang J, et al. Urethral reconstruction with small intestinal submucosa seeded with oral keratinocytes and TIMP-1 siRNA transfected fibroblasts in a rabbit model. Urol Int. 2016;96(2):223–30.View ArticlePubMedGoogle Scholar
- Nuininga JE, Koens MJ, Tiemessen DM, et al. Urethral reconstruction of critical defects in rabbits using molecularly defined tubular type I collagen biomatrices: key issues in growth factor addition. Tissue Eng Part A. 2010;16(11):3319–28.View ArticlePubMedGoogle Scholar
- Kropp BP, Ludlow JK, Spicer D, Rippy MK, Badylak SF, Adams MC, Keating MA, Rink RC, Birhle R, Thor KB. Rabbit urethral regeneration using small intestinal submucosa onlay grafts. Urology. 1998;52:138–42.View ArticlePubMedGoogle Scholar
- Fiala R, Vidlar A, Vrtal R, Belej K, Student V. Porcine small intestinal submucosa graft for repair of anterior urethral strictures. Eur Urol. 2007;51:1702–8. discussion 1708.View ArticlePubMedGoogle Scholar
- Wu S, Liu Y, Bharadwaj S, Atala A, Zhang Y. Human urine-derived stem cells seeded in a modified 3D porous small intestinal submucosa scaffold for urethral tissue engineering. Biomaterials. 2011;32(5):1317–26.View ArticlePubMedGoogle Scholar
- Zhang Y, McNeill E, Tian H, et al. Urine derived cells are a potential source for urological tissue reconstruction. J Urol. 2008;180(5):2226–33.View ArticlePubMedGoogle Scholar
- Zhang D, Wei G, Li P, Zhou X, Zhang Y. Urine-derived stem cells: a novel and versatile progenitor source for cell-based therapy and regenerative medicine. Genes Dis. 2014;1:8–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Urine-derived stem cells: a novel source for tissue engineering and regenerative medicine. J Biomater Tissue Eng. 2016;6:589–601.View ArticleGoogle Scholar
- Bharadwaj S, Liu G, Shi Y, et al. Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology. Stem Cells. 2013;31(9):1840–56.View ArticlePubMedGoogle Scholar
- Bharadwaj S, Liu G, Shi Y, et al. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A. 2011;17(15–16):2123–32.View ArticlePubMedGoogle Scholar
- Mundy AR. The long-term results of skin inlay urethroplasty. Br J Urol. 1995;75(1):59–61.View ArticlePubMedGoogle Scholar
- Barbagli G, Lazzeri M. Urethral reconstruction. Curr Opin Urol. 2006;16(6):391–5.View ArticlePubMedGoogle Scholar
- Andrich DE, Greenwell TJ, Mundy AR. The problems of penile urethroplasty with particular reference to 2-stage reconstructions. J Urol. 2003;170(1):87–9.View ArticlePubMedGoogle Scholar
- Fichtner J, Filipas D, Fisch M, Hohenfellner R, Thüroff JW. Long-term follow-up of buccal mucosa onlay graft for hypospadias repair: analysis of complications. J Urol. 2004;172(5 Pt 1):1970–2. discussion 1972.View ArticlePubMedGoogle Scholar
- Dublin N, Stewart LH. Oral complications after buccal mucosal graft harvest for urethroplasty. BJU Int. 2004;94(6):867–9.View ArticlePubMedGoogle Scholar
- Wood DN, Allen SE, Andrich DE, Greenwell TJ, Mundy AR. The morbidity of buccal mucosal graft harvest for urethroplasty and the effect of nonclosure of the graft harvest site on postoperative pain. J Urol. 2004;172(2):580–3.View ArticlePubMedGoogle Scholar
- Ahyai SA, Schmid M, Kuhl M, et al. Outcomes of ventral onlay buccal mucosa graft urethroplasty in patients after radiotherapy. J Urol. 2015;194(2):441–6.View ArticlePubMedGoogle Scholar
- Wang Y, Fu Q, Zhao RY, Deng CL. Muscular tubes of urethra engineered from adipose-derived stem cells and polyglycolic acid mesh in a bioreactor. Biotechnol Lett. 2014;36(9):1909–16.View ArticlePubMedGoogle Scholar
- Wang JH, Xu YM, Fu Q, et al. Continued sustained release of VEGF by PLGA nanospheres modified BAMG stent for the anterior urethral reconstruction of rabbit. Asian Pac J Trop Med. 2013;6(6):481–4.View ArticlePubMedGoogle Scholar
- Bolland F, Korossis S, Wilshaw SP, et al. Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering. Biomaterials. 2007;28(6):1061–70.View ArticlePubMedGoogle Scholar
- Zhang R, Ma PX. Synthetic nano-fibrillar extracellular matrices with predesigned macroporous architectures. J Biomed Mater Res. 2000;52(2):430–8.View ArticlePubMedGoogle Scholar
- Karande TS, Ong JL, Agrawal CM. Diffusion in musculoskeletal tissue engineering scaffolds: design issues related to porosity, permeability, architecture, and nutrient mixing. Ann Biomed Eng. 2004;32(12):1728–43.View ArticlePubMedGoogle Scholar
- Dorin RP, Pohl HG, De Filippo RE, Yoo JJ, Atala A. Tubularized urethral replacement with unseeded matrices: what is the maximum distance for normal tissue regeneration. World J Urol. 2008;26:323–6.View ArticlePubMedGoogle Scholar
- Feng C, Xu YM, Fu Q, Zhu WD, Cui L. Reconstruction of three-dimensional neourethra using lingual keratinocytes and corporal smooth muscle cells seeded acellular corporal spongiosum. Tissue Eng Part A. 2011;17:3011–9.View ArticlePubMedGoogle Scholar
- Parnigotto PP, Gamba PG, Conconi MT, Midrio P. Experimental defect in rabbit urethra repaired with acellular aortic matrix. Urol Res. 2000;28:46–51.View ArticlePubMedGoogle Scholar
- Nagele U, Maurer S, Feil G, Bock C, Krug J, Sievert KD, Stenzl A. In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol. 2008;54:1414–22.View ArticlePubMedGoogle Scholar
- Fu Q, Deng CL, Liu W, Cao YL. Urethral replacement using epidermal cell-seeded tubular acellular bladder collagen matrix. BJU Int. 2007;99:1162–5.View ArticlePubMedGoogle Scholar
- Feng C, Xu YM, Fu Q, Zhu WD, Cui L, Chen J. Evaluation of the biocompatibility and mechanical properties of naturally derived and synthetic scaffolds for urethral reconstruction. J Biomed Mater Res A. 2010;94:317–25.View ArticlePubMedGoogle Scholar
- Xie M, Xu Y, Song L, Wang J, Lv X, Zhang Y. Tissue-engineered buccal mucosa using silk fibroin matrices for urethral reconstruction in a canine model. J Surg Res. 2014;188:1–7.View ArticlePubMedGoogle Scholar
- Gu GL, Xia SJ, Zhang J, Liu GH, Yan L, Xu ZH, Zhu YJ. Tubularized urethral replacement using tissue-engineered peritoneum-like tissue in a rabbit model. Urol Int. 2012;89:358–64.View ArticlePubMedGoogle Scholar
- Zou XH, Zhi YL, Chen X, Jin HM, Wang LL, Jiang YZ, Yin Z, Ouyang HW. Mesenchymal stem cell seeded knitted silk sling for the treatment of stress urinary incontinence. Biomaterials. 2010;31:4872–9.View ArticlePubMedGoogle Scholar
- Bodin A, Bharadwaj S, Wu S, Gatenholm P, Atala A, Zhang Y. Tissue-engineered conduit using urine-derived stem cells seeded bacterial cellulose polymer in urinary reconstruction and diversion. Biomaterials. 2010;31:8889–901.View ArticlePubMedGoogle Scholar
- Pei M, Li J, Zhang Y, et al. Expansion on a matrix deposited by nonchondrogenic urine stem cells strengthens the chondrogenic capacity of repeated-passage bone marrow stromal cells. Cell Tissue Res. 2014;356(2):391–403.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu S, Wang Z, Bharadwaj S, et al. Implantation of autologous urine derived stem cells expressing vascular endothelial growth factor for potential use in genitourinary reconstruction. J Urol. 2011;186(2):640–7.View ArticlePubMedGoogle Scholar
- Wu RP, Soland M, Liu G, et al. Immunomodulatory properties of urine derived stem cells. 2012.Google Scholar